Edgar Filing: SEATTLE GENETICS INC /WA

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

BAKER FELIX

2. Issuer Name and Ticker or Trading Symbol
SEATTLE GENETICS INC /WA [SGEN]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

667 MADISON AVENUE, 21ST FLOOR

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2016

(Street)

NEW YORK, NY 10065

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								107,511 ⁽¹⁾	D
Common Stock								107,504 ⁽²⁾	D
Common Stock	09/09/2016		P		3,181	A	$ 50.5452 ⁽³⁾	4,673,896	I	See footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		28,271	A	$ 50.5452 ⁽³⁾	39,058,639	I	See footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		894	A	$ 51.05 ⁽⁶⁾	4,674,790	I	See footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		7,944	A	$ 51.05 ⁽⁶⁾	39,066,583	I	See footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		19,201	A	$ 50.3787 ⁽⁷⁾	4,693,991	I	See footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		170,652	A	$ 50.3787 ⁽⁷⁾	39,237,235	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		2,637	A	$ 50.3266 ⁽⁸⁾	4,696,628	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/09/2016		P		23,440	A	$ 50.3266 ⁽⁸⁾	39,260,675	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		3,728	A	$ 51.2545 ⁽⁹⁾	4,700,356	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		33,241	A	$ 51.2545 ⁽⁹⁾	39,293,916	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		262	A	$ 50.4829 ⁽¹⁰⁾	4,700,618	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		2,338	A	$ 50.4829 ⁽¹⁰⁾	39,296,254	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		940	A	$ 50.9864 ⁽¹¹⁾	4,701,558	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		8,380	A	$ 50.9864 ⁽¹¹⁾	39,304,634	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		101	A	$ 49.835	4,701,659	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/12/2016		P		899	A	$ 49.835	39,305,533	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		10	A	$ 50	4,701,669	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		90	A	$ 50	39,305,623	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		2,388	A	$ 50.4082 ⁽¹²⁾	4,704,057	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		21,290	A	$ 50.4082 ⁽¹²⁾	39,326,913	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		2,445	A	$ 50.4214 ⁽¹³⁾	4,706,502	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		21,804	A	$ 50.4214 ⁽¹³⁾	39,348,717	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		101	A	$ 50.637 ⁽¹⁴⁾	4,706,603	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		899	A	$ 50.637 ⁽¹⁴⁾	39,349,616	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		6,565	A	$ 51.4057 ⁽¹⁵⁾	4,713,168	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		58,541	A	$ 51.4057 ⁽¹⁵⁾	39,408,157	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		2,730	A	$ 51.5457 ⁽¹⁶⁾	4,715,898	I	See Footnote ⁽⁴⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾
Common Stock	09/13/2016		P		24,339	A	$ 51.5457 ⁽¹⁶⁾	39,432,496	I	See Footnote ⁽⁵⁾ ⁽¹⁷⁾ ⁽¹⁸⁾ ⁽¹⁹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY New York	X	X
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
667, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
Baker Brothers Life Sciences LP 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X

Signatures

/s/ Felix J. Baker		09/13/2016
^**Signature of Reporting Person		Date
/s/ Julian C. Baker		09/13/2016
^**Signature of Reporting Person		Date
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		09/13/2016
^**Signature of Reporting Person		Date
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		09/13/2016
^**Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		09/13/2016
^**Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P. Name: Scott L. Lessing /s/ Scott L. Lessing		09/13/2016
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Reflects shares of common stock of Seattle Genetics, Inc. (the "Issuer") held directly by Felix J. Baker.
(2)	Reflects shares of common stock of the Issuer held directly by Julian C. Baker.
(3)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences") in multiple transactions at prices ranging from $50.24 to $50.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(4)	After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
(5)	After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences
(6)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $51.05 to $51.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(7)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.16 to $50.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(8)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.17 to $50.61, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(9)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.66 to $51.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(10)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.42 to $50.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(11)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.70 to $51.33, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(12)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.15 to $50.72, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(13)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.20 to $50.64, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(14)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.56 to $50.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(15)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.73 to $51.72, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(16)	The price reported in Column 4 is a weighted average price. These shares were purchased by 667 and Life Sciences in multiple transactions at prices ranging from $50.99 to $51.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
(17)	Includes beneficial ownership of 14,400 previously issued restricted stock units payable solely in common shares issued to Felix Baker in his capacity as a director of the Issuer pursuant to the Amended and Restated 2007 Equity Incentive Plan of which the fund may be deemed to own a portion and 30,000 shares received previously from exercise of 30,000 stock options of the Issuer that were issued to Felix J. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
(18)	Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to Life Sciences and 667 (collectively the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
(19)	Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Remarks: Felix J. Baker is a director of Seattle Genetics, Inc. (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.